Damora Therapeutics, Inc. short interest in 2022
In 2022, Damora Therapeutics, Inc.'s disclosed short interest ran from 0.31% of shares outstanding on 14 Jan 2022 to 0.26% on 30 Dec 2022, a change of -0.05 percentage points. The year's high was 0.47% on 31 Jan 2022 and its low 0.09% on 29 Apr 2022, averaging 0.21% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 1.51 days on 15 Feb 2022. Full history: Damora Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2022 in figures
- Start of year
- 0.31% (14 Jan 2022)
- End of year
- 0.26% (30 Dec 2022)
- Change
- -0.05 pp
- High
- 0.47% (31 Jan 2022)
- Low
- 0.09% (29 Apr 2022)
- Average
- 0.21%
- Highest days to cover
- 1.51 (15 Feb 2022)
- SEC filings marked
- 4
Every report in 2022
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Jan 2022 | 0.31% | 1.00 | |
| 31 Jan 2022 | 0.47% | 1.17 | |
| 15 Feb 2022 | 0.36% | 1.51 | |
| 28 Feb 2022 | 0.26% | 1.10 | 10-K filed |
| 15 Mar 2022 | 0.36% | 1.43 | |
| 31 Mar 2022 | 0.24% | 1.00 | |
| 14 Apr 2022 | 0.24% | 1.00 | |
| 29 Apr 2022 | 0.09% | 1.00 | 10-Q filed |
| 13 May 2022 | 0.11% | 1.00 | |
| 31 May 2022 | 0.20% | 1.00 | |
| 15 Jun 2022 | 0.17% | 1.00 | |
| 15 Jul 2022 | 0.23% | 1.51 | |
| 29 Jul 2022 | 0.20% | 1.45 | 10-Q filed |
| 15 Aug 2022 | 0.20% | 1.00 | |
| 31 Aug 2022 | 0.18% | 1.00 | |
| 15 Sep 2022 | 0.15% | 1.00 | |
| 30 Sep 2022 | 0.20% | 1.00 | |
| 14 Oct 2022 | 0.17% | 1.02 | |
| 31 Oct 2022 | 0.09% | 1.00 | |
| 15 Nov 2022 | 0.09% | 1.00 | 10-Q filed |
| 30 Nov 2022 | 0.09% | 1.00 | |
| 15 Dec 2022 | 0.11% | 1.00 | |
| 30 Dec 2022 | 0.26% | 1.00 |
See also: Damora Therapeutics, Inc.'s full history · most shorted US stocks of 2022 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.